Publications by authors named "Markus Jensen"

Claim this Profile
P
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients.
Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen

CPT Pharmacometrics Syst Pharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Diet on Serum Creatinine in Healthy Subjects During a Phase I Study.
Eduardo Pimenta, Markus Jensen, David Jung, Frank Schaumann, Stefanie Boxnick

J Clin Med Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Andrew X Zhu, Olivier Rosmorduc, T R Jeffry Evans, Paul J Ross, Armando Santoro, Markus Jensen

J Clin Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seventy-five years of Resochin in the fight against malaria.
Markus Jensen, Heinz Mehlhorn

Parasitol Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
Martin Klehr, Ulrike Koehl, Martina Mühlenhoff, Samir Tawadros, Thomas Fischer, Markus Jensen

J Immunother· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.
Markus Jensen, Andreas Engert, Florian Weissinger, Wolfgang Knauf, Eva Kimby

Invest New Drugs· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the neural cell adhesion molecule in cancer.
Markus Jensen, Frank Berthold

Cancer Lett· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One step generation of fully chimeric antibodies using Cgamma1- and Ckappa mutant mice.
Markus Jensen, Martin Klehr, Anna Vogel, Sandra Schmitz, Samir Tawadros

J Immunother· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab.
Markus Jensen, Thomas Elter, Andreas Engert, Marcel Reiser

Onkologie· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice.
Christina Otto, Markus Jensen, Markus Dietlein, Thomas Fischer, Matthias Schmidt

Nucl Med Commun· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Thomas Elter, Peter Borchmann, Holger Schulz, Marcel Reiser, Sven Trelle, Markus Jensen

J Clin Oncol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
Marc Beyer, Matthias Kochanek, Kamruz Darabi, Alexey Popov, Markus Jensen

Blood· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation and evaluation of a central coordination office for clinical trials in a tertiary care hospital.
Sven Trelle, Jan Oliver Staak, Markus Jensen, Andreas Engert, Marcel Reiser

Onkologie· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK cell depletion diminish tumour-specific B cell responses.
Markus Jensen, Samir Tawadros, Hans-Harald Sedlacek, Joachim L Schultze, Frank Berthold

Immunol Lett· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis